



Antibiotic Resistance in *Pseudomonas aeruginosa*: Mechanisms and Therapeutic Approach

Guest Editors:

Prof. Dr. Christian Hulen

Laboratory of Microbiology –
Bacterial Communication and
Anti-Infectious Strategies,
University of Rouen Normandy,
27000 Evreux, France

Prof. Dr. Olivier Lesouhaitier

Laboratory of Microbiology –
Bacterial Communication and
Anti-infectious Strategies,
University of Rouen Normandy,
27000 Evreux, France

Deadline for manuscript
submissions:

closed (30 June 2024)

Message from the Guest Editors

Pseudomonas aeruginosa regarding its antibiotic resistance is one of the six ESKAPE pathogens with the highest risk of mortality, particularly in developing countries belongs. The World Health Organization as classified this pathogen as priority 1 (critical) for its resistance to carbapenem needing to urgently find new to counteract *P.aeruginosa*. The presence in numerous human environments of MDR *P. aeruginosa* poses a major health problem for the treatment of sporadic or chronic infections and for the appearance of persisters bacteria. In this special issue we would like to first review recent data on the mechanisms of resistance of *P. aeruginosa* to antibiotics and growth inhibitors. The presentation of new fields of research for the development of new therapeutic strategies to fight against multiresistance, proliferation and persistence of *P. aeruginosa* should be the subject of a second part. In addition, innovative manuscripts whose subject approaches the themes of this special issue may be analyzed. Resistance of *P. aeruginosa* to antibiotics and new therapeutic strategies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi